Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 27 november att bolaget har testat ...
STENOCARE announced on November 26th the STENOCARE 3.
Fortsatt svag konsumentmarknad Omsättningen i det tredje kvartalet minskade med 13,3 procent, vilket...
Redeye comments on FluoGuide’s Q3 2024 report, following its recent business update on FG001’s plann...
Redeye shares its initial take on TH1NG’s Q3 report, in which revenues were in line with our modest ...
Redeye briefly comments on the positive news that Saniona has outlicensed SAN711 to Acadia in neurol...
Educational day with presentations from core holdings DP Patterning: small initial investment, large...
Redeye shares its key takeaways and nuggets from Devyser’s Capital Markets Day.
De diskussioner som Eastnine bekräftade i början av november har idag mynnat ut i ett jätteförvärv a...
Vaxxa är ett e-handelsbolag som driver en digital auktionstjänst, där bolaget syftar till att erbjud...
Redeye comments on Freemelt’s agreement with another leading global orthopedic implant OEM.
Redeye returns following Kancera’s strategic shift to focus on cardiovascular diseases and its Q3 re...
Redeye provides a research update following the Pharmanovia’s decision to discontinue the partnershi...
ODI Pharma published on November 22nd the company’s Q1-report for 2024/2025.
Analyst Group har med Titania ingått avtal om kontinuerlig analysbevakning, innefattande bl.
